Description:
Crystallization is an industrially important unit operation for isolation and purification of a wide range of chemical products, including pharmaceuticals and fine chemicals. Developing a continuous crystallization process can be challenging, often complicated by multiple components and requirements that the solids are consistently isolated in the desired polymorphic forms, compounds, adducts, or solvates. Control of particle size distribution may be needed to avoid difficult filtrations or high impurity content. This session welcomes contributions related to theoretical as well as practical approaches to continuous crystallization process development, including techniques and tools that can lead to more efficient development of robust continuous crystallization processes. Case studies and examples of how commercial continuous crystallization processes are developed, and papers which describe the design and operation of continuous crystallization processes are particularly encouraged. Examples of integration with other continuous unit operations – distillation, liquid-liquid separation, membrane separation, solid-liquid separation/filtration, drying, wet milling, or reactions – are also highly encouraged.
Sponsor:
Crystallization and Evaporation
Co-Sponsor(s):
Pharmaceutical Discovery, Development and Manufacturing Forum (26)
Chair:
Christopher L. Burcham
Senior Engineering Research Advisor
Eli Lilly and Company
Indianapolis, IN
46285
Email: cburcham@lilly.com
Senior Engineering Research Advisor
Eli Lilly and Company
Indianapolis, IN
46285
Email: cburcham@lilly.com
Co-Chair:
Xiaochuan Yang
Visiting Associate
Office of Pharmaceutical Quality, U.S. Food and Drug Administration
Silver Spring, MD
Email: Xiaochuan.Yang@fda.hhs.gov
Visiting Associate
Office of Pharmaceutical Quality, U.S. Food and Drug Administration
Silver Spring, MD
Email: Xiaochuan.Yang@fda.hhs.gov
Papers:
Abstract Submissions Closed
See more of this Group/Topical: Separations Division
